Event > Conference >
This year’s AASLD Conference will discuss the latest research on disease states like NAFLD, NASH, and Hepatitis. While educational sessions from leading hepatologists and public health experts will run alongside. Or delve deep with a niche session from one of the leading minds in the Meet-the-Expert sessions. The patient’s perspective will also be presented by the Patient Advocacy Group programming.
Will you be there too?
Head to our exhibition stand – #642
We look forward to meeting you to discuss how to improve the predictability of human toxicity using Organ-on-a-Chip. Reveal the mechanisms of drug-induced liver injury (DILI) with PhysioMimix® OOC single-and multi-organ microphysiological systems.
Modeling the intestine-liver axis and the role of the FXR agonists in a multi-organ microphysiological system model of Non-Alcoholic Fatty Liver Disease
The human liver and gut are uniquely linked and play a crucial role in controlling the pathology of the liver. It has been proposed that changes in this gut-liver axis is tightly linked with the progression of non-alcoholic fatty liver disease (NAFLD) into non-alcoholic steatohepatitis (NASH).
As there are currently no FDA-approved drugs for the treatment of NAFLD/NASH, there is a clear requirement to better understand the mechanisms that drive disease progression to better inform therapeutic R&D programs. Unfortunately, traditional in vivo and in vitro preclinical models of NAFLD and NASH suffer from shortfalls that limit their predictability. No one model can fully recapitulate the key aspects of NAFLD/NASH. Moreover, very few accurately capture the human gut-liver axis and enable studies into the molecular mechanisms that drive NAFLD progression.
Here, we demonstrate the potential of a liver and a gut/liver microphysiological systems (MPS) to recapitulate NAFLD and NASH phenotypes in vitro and explore the molecular mechanisms underlying the development of NAFLD/NASH as well as assess the efficacy of novel therapeutic strategies.
Date: Monday, November 7, 2022
Room: Poster Hall
Presentation from: Dr Tomasz Kostrzewski, CN Bio
Abstract number: 4310
Our Team at AASLD
Dr Tomasz Kostrzewski is VP – Science and Technology at CN Bio with more than 15 years of experience in molecular and cellular biology research. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation. At Imperial College London he completed both an MRes and PhD in the department of Cell and Molecular Biology. He has significant experience in advanced (3D) mammalian cell culture, gene expression analysis and immune cell function. Additionally, he has previous experience of working in biopharmaceutical drug discovery and development with GlaxoSmithKline. In 2017, he was promoted to head of biology at CN Bio and is responsible for biological model development and collaborative research projects and in 2022 he took responsibility for all technical activities including developing new products, technologies and assays. TK has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. TK has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Dr Brian Manning – Global Head of Sales, is a PhD-qualified pharmacologist, Brian trained in Ireland, France, and the USA before spending 10 years in Big Pharma drug discovery, where he also completed his MBA. He joined CN Bio Innovations in 2020 and prior to that, had a successful career in delivering rapid sales growth for cutting-edge cell culture companies in the UK and US, specializing in organ-on-chip and spheroid cultures over the last 6 years. Currently based in New Jersey, USA, Dr. Manning holds a PhD from the National University of Ireland an MBA from Rensselaer Polytechnic Institute.
James Ferritto is the Western US Sales Manager for CN Bio, based out of the Bay Area. In his role, James supports researchers looking to bring more predictive data to their drug development process. He has a track record of helping scientists identify & implement new technologies to improve research outcomes. James is excited by the PhysioMimix® Organ-on-Chip platform since he has experienced how it enables more relevant decision-making in preclinical stages. James holds a BS from Boston University (US).
Dr. Anthony Berger is CN-Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).
Dr Scott Chilton is the Eastern US Sales Manager for CN Bio, based in Massachusetts, USA. Scott supports researchers who want to develop safe and effective therapeutics faster and more cost-effectively by adopting solutions that provide physiologically relevant and clinically translatable data. Scott holds a PhD from Harvard University and a BS from Massachusetts Institute of Technology.